Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
Hutchmed
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
48High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05720767CT.gov HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study | — | Completed | — | — | — |
NCT01844583CT.gov Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib | — | Completed | — | — | — |
NCT01454076CT.gov Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma | — | Completed | — | — | — |
NCT01324323CT.gov Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer | — | Completed | — | — | — |
NCT01121133CT.gov A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Rifaldazine (this asset) | Hutchmed | P1 | CCC · 52 |
| Vinblastine | Intensity Therapeutics, Inc. | P4 | BBB |
| Prednisolone | The Lymphoma Academic Research Organisation | P4 | BBB |
| Vincristine Sulfate | Inhye Ahn | P3 | BB |
| Cyclophosphamide | Beth Israel Deaconess Medical Center | P4 | BB |
| Bleomycin | Shandong Provincial Hospital | P4 | BB |
| Methotrexate | University of Chicago | P4 | BB |
| Rituximab | City of Hope Medical Center | P4 | BB |
| Isocyclophosphamide | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | P3 | BB |
+42 more in the Lymphoma cohort
Other indications for Rifaldazine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Methicillin-Resistant Staphylococcus Aureus Infectious Disease | — | P4 | BB · 71 |
| Cystic Fibrosis | — | P4 | BB · 65 |
| Metabolic Dysfunction-Associated Steatotic Liver Disease | — | P4 | B · 62 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Rifaldazine in Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/rifaldazine-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →